#1 Clinical Trials Search in Europe

Fostemsavir Trometamol

Fostemsavir Trometamol, marketed as Rukobia, is being studied in clinical trials for people living with HIV-1 who have limited treatment options. This article explores a Phase IV clinical trial called FOST Switch, which aims to evaluate the effectiveness and safety of switching from a boosted protease inhibitor to Fostemsavir in HIV-1 patients with limited therapeutic choices. The trial focuses on viral suppression, patient safety, and quality of life improvements.

Table of Contents

What is Fostemsavir?

Fostemsavir trometamol, marketed under the brand name Rukobia, is a medication used to treat HIV-1 infection in adults who have limited treatment options[1]. It is a new type of antiretroviral drug that offers hope for people living with HIV (PLWH) who have developed resistance to other HIV medications or have limited therapeutic choices due to intolerance to previous treatments.

How Fostemsavir Works

Fostemsavir belongs to a class of drugs called attachment inhibitors. It works differently from other HIV medications by preventing the virus from attaching to and entering CD4 cells (important immune system cells targeted by HIV). By blocking this initial step in the HIV life cycle, fostemsavir helps to reduce the amount of virus in the body and protect the immune system[1].

Who Can Benefit from Fostemsavir?

Fostemsavir is specifically designed for adults with HIV-1 who have:

  • Limited treatment options due to resistance to multiple HIV medications
  • Experienced intolerance to other antiretroviral therapies
  • Been on a stable HIV treatment regimen but need to switch due to side effects or drug interactions with their current medications

It’s important to note that fostemsavir is not recommended for people with HIV-1 subtype AE, as it may not be effective against this particular strain of the virus[1].

Dosage and Administration

Rukobia (fostemsavir) comes in the form of 600 mg prolonged-release tablets. The recommended dosage is one tablet taken orally twice daily[1]. The maximum daily dose is 600 mg, and the medication is typically prescribed for extended periods, with clinical trials evaluating its use for up to 48 weeks.

Clinical Trial Details

A clinical trial called “FOST Switch” is currently evaluating the efficacy and safety of switching from a boosted protease inhibitor (a type of HIV medication) to fostemsavir in people living with HIV who have limited treatment options[1]. The main goals of this trial include:

  • Assessing the proportion of patients with HIV viral load below 50 copies/mL at 48 weeks (indicating good viral suppression)
  • Evaluating changes in CD4 cell counts and other immune system markers
  • Monitoring safety and tolerability of fostemsavir
  • Assessing patient-reported benefits and quality of life improvements

Potential Benefits of Switching to Fostemsavir

Switching to fostemsavir may offer several potential benefits for eligible patients[1]:

  1. Improved viral suppression: Fostemsavir may help maintain or achieve undetectable viral loads in patients with limited treatment options.
  2. Enhanced immune function: The medication aims to improve CD4 cell counts and overall immune system health.
  3. Reduced drug interactions: Fostemsavir may have fewer drug interactions compared to some other HIV medications, potentially simplifying treatment for patients taking multiple medications.
  4. Improved quality of life: The clinical trial is assessing changes in patient-reported outcomes, including overall well-being and mental health.
  5. Convenience: The twice-daily oral dosing may be more convenient for some patients compared to their previous regimens.

Safety and Side Effects

The clinical trial is closely monitoring the safety and tolerability of fostemsavir. Some areas of focus include[1]:

  • Occurrence and severity of adverse events
  • Changes in lipid levels (fats in the blood)
  • Effects on glucose metabolism and insulin resistance
  • Changes in weight and waist circumference
  • Impacts on bone health, kidney function, and cardiovascular risk

As with any medication, it’s important to discuss potential side effects and risks with your healthcare provider.

Important Considerations and Precautions

When considering fostemsavir as a treatment option, keep in mind the following[1]:

  • Fostemsavir is not recommended for patients with severe liver impairment (Child-Pugh Class C).
  • It should not be used by patients with a history of certain heart conditions, including congestive heart failure or congenital long QT syndrome.
  • Pregnant or breastfeeding women should discuss the potential risks and benefits with their healthcare provider.
  • Fostemsavir may interact with certain medications, so it’s crucial to inform your doctor about all drugs, supplements, and herbal products you’re taking.

In conclusion, fostemsavir (Rukobia) represents a promising new treatment option for people living with HIV-1 who have limited choices due to treatment resistance or intolerance. If you think you might be eligible for this medication, discuss it with your HIV care provider to determine if it’s an appropriate option for your individual situation.

Aspect Details
Trial Name FOST Switch
Drug Fostemsavir Trometamol (Rukobia)
Trial Phase Phase IV
Main Objective Assess proportion of patients with HIV viral load ≥ 50 copies/mL at week 48
Key Eligibility Criteria HIV-1 infected adults, stable suppressive cART, on boosted protease inhibitor
Duration 48 weeks
Key Endpoints Viral load, CD4 count, safety, tolerability, quality of life
Dosage 600 mg daily (maximum)
Administration Route Oral

FAQ

  • What is Fostemsavir Trometamol? Fostemsavir Trometamol, marketed as Rukobia, is a medication used to treat HIV-1 infection in adults with limited treatment options. It is a new type of antiretroviral drug that works differently from other HIV medications.
  • Who is eligible for the FOST Switch clinical trial? The trial is open to HIV-1 infected adults over 18 years old who are on a stable and suppressive antiretroviral therapy with a viral load ≤50 copies/mL for 1 year. Participants must be currently on a boosted protease inhibitor and have no other potential switch options due to intolerance or resistance to prior therapies.
  • What is the main goal of the FOST Switch trial? The primary objective of the trial is to assess the proportion of patients with HIV viral load ≥ 50 copies/mL at week 48 after switching to Fostemsavir. This helps determine if Fostemsavir is effective in maintaining viral suppression.
  • How long does the FOST Switch trial last? The trial lasts for 48 weeks (about 11 months). During this time, participants will be monitored for viral load, CD4 count, safety, and quality of life measures.
  • What are some of the potential benefits of switching to Fostemsavir? The trial aims to evaluate potential benefits such as improved viral suppression, better CD4 counts, fewer drug interactions, improved safety and tolerability, and enhanced quality of life for patients. It may offer a new treatment option for those with limited choices due to resistance or intolerance to other HIV medications.

Ongoing Clinical Trials on Fostemsavir Trometamol

  • Study on Switching from Boosted Protease Inhibitors to Fostemsavir for People with HIV-1 with Limited Treatment Options

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Italy Spain

Glossary

  • Fostemsavir Trometamol: An antiretroviral medication used to treat HIV-1 infection in adults with limited treatment options. It is marketed under the brand name Rukobia.
  • HIV-1: Human Immunodeficiency Virus type 1, the most common type of HIV that causes AIDS (Acquired Immunodeficiency Syndrome).
  • Viral load: The amount of HIV in a person's blood. A lower viral load indicates better control of the virus.
  • CD4 count: A measure of the number of CD4 T cells in the blood. These cells are important for the immune system, and a higher count is generally better for people with HIV.
  • Boosted protease inhibitor: A type of HIV medication that is combined with another drug to increase its effectiveness in fighting the virus.
  • cART: Combination Antiretroviral Therapy, a treatment approach that uses multiple HIV medications to suppress the virus.
  • Drug-drug interactions: When one medication affects how another medication works in the body, potentially causing unwanted effects or reduced effectiveness.
  • QT interval: A measurement on an electrocardiogram that represents the time it takes for the heart to recharge between beats. Certain medications can affect this interval.
  • ALT: Alanine Aminotransferase, a liver enzyme that can indicate liver health or damage when measured in blood tests.
  • HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, a method used to quantify insulin resistance and beta-cell function.

References

  1. http://clinicaltrials.eu/trial/study-on-switching-from-boosted-protease-inhibitors-to-fostemsavir-for-people-with-hiv-1-with-limited-treatment-options/